Nevertheless, as CD84 has also been found to be expressed by other immune cell types including macrophages, B cells and T cells [109, 110], and in the latter contributes to stimulating IFNγ release [111], strategies that target CD84 to deplete or inhibit MDSCs may lead to off-target effects and simultaneously impair anti-tumour T cell activity. This evidence concerns the gene IFNG and neoplasm.